Nkarta reports moderate or major responses in 5 of 6 myositis patients in NKX019 trial

• Nkarta announced initial NKX019 trial results showing clinical improvement in most evaluable patients with treatment-resistant myositis or systemic sclerosis.
• Myositis responses included improved muscle strength; systemic sclerosis patients showed rapid reductions in skin thickening.
• Safety findings across 40 patients showed no deaths, treatment discontinuations due to adverse events or immune effector cell-associated toxicities.
• Results are being presented at ACR Convergence 2026; additional integrated safety data will be presented November 11.
• FDA discussions on potential registrational pathways are planned, with additional follow-up results and a registrational dose-selection plan expected in first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872946) on November 09, 2026, and is solely responsible for the information contained therein.